Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:ATAI NASDAQ:CABA NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$18.27$15.18$5.97▼$19.15$2.03B-0.21.82 million shs1.39 million shsATAIAtai Beckley$5.19$4.32$2.53▼$6.75$1.91B1.569.19 million shs11.33 million shsCABACabaletta Bio$3.19$3.31$1.26▼$4.23$520.15M3.265.88 million shs8.58 million shsNUVBNuvation Bio$5.69-0.3%$5.00$2.01▼$9.75$1.98B1.528.38 million shs6.33 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+2.70%+27.67%+22.21%+178.08%ATAIAtai Beckley0.00%-1.89%+15.33%+36.94%+88.73%CABACabaletta Bio0.00%+4.93%-9.12%+7.77%+99.38%NUVBNuvation Bio0.00%+1.43%+9.86%+27.90%+176.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$18.27$15.18$5.97▼$19.15$2.03B-0.21.82 million shs1.39 million shsATAIAtai Beckley$5.19$4.32$2.53▼$6.75$1.91B1.569.19 million shs11.33 million shsCABACabaletta Bio$3.19$3.31$1.26▼$4.23$520.15M3.265.88 million shs8.58 million shsNUVBNuvation Bio$5.69-0.3%$5.00$2.01▼$9.75$1.98B1.528.38 million shs6.33 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+2.70%+27.67%+22.21%+178.08%ATAIAtai Beckley0.00%-1.89%+15.33%+36.94%+88.73%CABACabaletta Bio0.00%+4.93%-9.12%+7.77%+99.38%NUVBNuvation Bio0.00%+1.43%+9.86%+27.90%+176.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.90Moderate Buy$24.2532.73% UpsideATAIAtai Beckley 2.91Moderate Buy$16.00208.29% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50385.89% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50119.88% UpsideCurrent Analyst Ratings BreakdownLatest CABA, AMLX, NUVB, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026AMLXAmylyx Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.006/24/2026ATAIAtai Beckley Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/8/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.006/8/2026ATAIAtai Beckley HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026ATAIAtai Beckley AegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M23.25N/AN/A$2.78 per share6.57ATAIAtai Beckley$4.09M467.19N/AN/A$0.69 per share7.52CABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ANUVBNuvation Bio$62.90M31.47N/AN/A$0.88 per share6.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)ATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)Latest CABA, AMLX, NUVB, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AATAIAtai BeckleyN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85ATAIAtai BeckleyN/AN/AN/ACABACabaletta BioN/A2.952.95NUVBNuvation Bio0.157.447.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%ATAIAtai Beckley28.41%CABACabaletta BioN/ANUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals10.90%ATAIAtai Beckley26.80%CABACabaletta Bio6.44%NUVBNuvation Bio30.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million99.07 millionOptionableATAIAtai Beckley80368.17 million269.50 millionOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionableCABA, AMLX, NUVB, and ATAI HeadlinesRecent News About These CompaniesIs Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?July 2 at 8:03 AM | finance.yahoo.comNuvation Bio Issues Convertible Notes, Retires Secured DebtJune 30, 2026 | tipranks.comNuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?June 29, 2026 | fool.comNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United KingdomJune 29, 2026 | prnewswire.comKerry Wentworth Sells 63,000 Shares of Nuvation Bio (NYSE:NUVB) StockJune 26, 2026 | americanbankingnews.comStacy Markel Sells 125,000 Shares of Nuvation Bio (NYSE:NUVB) StockJune 26, 2026 | americanbankingnews.comNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesJune 25, 2026 | prnewswire.comWhy is NUVB stock falling today?June 25, 2026 | msn.comNuvation Bio Announces Proposed Convertible Senior Notes OfferingJune 25, 2026 | prnewswire.comNuvation Bio (NYSE:NUVB) CFO Philippe Sauvage Sells 47,668 Shares of StockJune 25, 2026 | insidertrades.comWhy Nuvation Bio (NYSE:NUVB) Is Becoming A Small-Cap Stock To Watch?June 23, 2026 | kalkinemedia.comKNuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 22, 2026 | marketbeat.comNuvation Bio (NYSE:NUVB) Leads Biotech Penny WatchJune 19, 2026 | kalkinemedia.comKIshara Investments LP Buys New Shares in Nuvation Bio Inc. $NUVBJune 18, 2026 | marketbeat.comACT Capital Management LLC Makes New $5.47 Million Investment in Nuvation Bio Inc. $NUVBJune 18, 2026 | marketbeat.comNuvation Bio Inc. $NUVB Stock Holdings Lowered by Omega Fund Management LLCJune 17, 2026 | marketbeat.comWhy Nuvation Bio Is Turning Heads As A Biotech Penny Stock?June 17, 2026 | kalkinemedia.comKHere’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)June 17, 2026 | finance.yahoo.comWhy Is Nuvation Bio Back On Penny Stock Watchlists?June 16, 2026 | kalkinemedia.comKNuvation Bio: David Hung's Latest Venture Looks Undervalued At Current LevelJune 15, 2026 | seekingalpha.comNuvation Bio (NYSE:NUVB) Director Robert Mashal Purchases 25,000 SharesJune 12, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, AMLX, NUVB, and ATAI Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$18.27 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$18.30 +0.03 (+0.14%) As of 07/2/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Atai Beckley NASDAQ:ATAI$5.19 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.17 -0.02 (-0.39%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Cabaletta Bio NASDAQ:CABA$3.19 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.18 -0.01 (-0.38%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Nuvation Bio NYSE:NUVB$5.68 -0.02 (-0.26%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$5.73 +0.05 (+0.79%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
